BioCryst Pharmaceuticals Appoints Babar Ghias as CFO and Head of Corporate Development: A Step Towards Enhanced Growth Strategies
ByAinvest
Monday, Jul 7, 2025 2:17 pm ET1min read
BCRX--
MPC--
BioCryst Pharmaceuticals has appointed Babar Ghias as CFO to enhance growth and capital deployment strategies. Ghias has extensive experience in finance and operations within the biotech sector, particularly in rare diseases. His background includes senior positions at Paragon Biosciences and Marathon Pharmaceuticals, where he played key roles in capital raising and preparing companies for commercial launch. CEO Jon Stonehouse expressed confidence that Ghias's expertise will support BioCryst’s growth strategy and capitalize on the commercial success of their product ORLADEYO.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet